Patients with hepatitis due to an irAE are usually asymptomatic and detected by routine liver function assessments, although patients may present with fever, jaundice, and abdominal pain.37,75 Immune-related adverse events affecting the liver typically occur 6–14 weeks after beginning therapy.35–37,75 Liver function tests including aspartate transaminase and alanine aminotransferase, as well as bilirubin, are increased, and the symptoms and levels of elevation determine the severity.37,75 Fulminant hepatic failure and death are rare. This evidence concerns the gene GPT and Hepatic failure.